Safety and Efficacy of Lorbrena

Recruiting

• Conditions: Non-small Cell Lung Cancer

• Registration Number: NCT03844464
• Lead Sponsor: Pfizer

Brief Summary

To investigate the following matters under post-marketing use of Lorbrena in patients who received this drug

1. Factors affecting the onset of central nervous system disorder

2. Effect of Lorbrena in combination with CYP3A inducers on the onset of hepatic dysfunction

Detailed Description

Not available

Study Timeline

• Study Start: 2019-01-21
• Study First Submitted: 2019-02-15
• Study First Submitted QC: 2019-02-15
• Study First Posted: 2019-02-18
• Status Verified: 2023-12
• Last Update Submitted: 2023-12-22
• Last Update Posted: 2023-12-26
• Primary Completion: 2025-12-31
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 683

Inclusion Criteria

• All administered patients

Read More

Exclusion Criteria

• Nothing

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of adverse drug reactions of central nervous system disorder and hepatic dysfunction	52 weeks

Trial Locations

Locations (1)

3-22-7, Yoyogi, Shibuya-ku; 🇯🇵 Tokyo, Japan